2019 Update of InVivo Therapeutics Corp – Product Pipeline Analysis – ResearchAndMarkets.com

February 13, 2020 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “InVivo Therapeutics Corp – Product Pipeline Analysis, 2019 Update” company profile has been added to ResearchAndMarkets.com’s offering.


InVivo Therapeutics Corp (InVivo), a subsidiary of InVivo Therapeutics Holdings Corp, is a medical device company that offers therapeutic products. The company develops and commercializes groundbreaking treatments for spinal cord injuries. Its products include biocompatible neuro spinal scaffold to treat acute SCI, and a biocompatible neuro spinal scaffold plus stem cells to treat chronic. InVivo offers treatment for mechanical injury directly disrupts axons, blood vessels, and cell membranes; and compressive-contusive-type injuries. The company provides services in the field of spinal cord injury. Its pipeline products comprise neuro-spinal scaffold, and bioengineered neural trails. InVivo is headquartered in Cambridge, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company InVivo Therapeutics Corp
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Key Topics Covered:

  • InVivo Therapeutics Corp Company Overview
  • InVivo Therapeutics Corp Company Snapshot
  • InVivo Therapeutics Corp Pipeline Products and Ongoing Clinical Trials Overview
  • InVivo Therapeutics Corp – Pipeline Analysis Overview
  • InVivo Therapeutics Corp – Key Facts
  • InVivo Therapeutics Corp – Major Products and Services
  • InVivo Therapeutics Corp Pipeline Products by Development Stage
  • InVivo Therapeutics Corp Ongoing Clinical Trials by Trial Status
  • InVivo Therapeutics Corp Pipeline Products Overview
  • Dural Graft
  • Dural Graft Product Overview
  • Injectable Hydrogel – Fibrosis
  • Injectable Hydrogel – Fibrosis Product Overview
  • Injectable Hydrogel – Peripheral Nerve Pain
  • Injectable Hydrogel Device – Acute SCI
  • InVivoSeal
  • InVivoSeal Product Overview
  • Nerve Conduit
  • Nerve Conduit Product Overview
  • Neuro-Spinal Scaffold – Acute Complete Cervical SCI
  • Neuro-Spinal Scaffold – Acute Complete Thoracic SCI
  • Neuro-Spinal Scaffold – Acute Complete Thoracic SCI Clinical Trial
  • Neuro-Spinal Scaffold – Incomplete Thoracic & Cervical SCI
  • Spinal Multi – Segmental Cell and Drug Delivery System
  • TrailMaker
  • TrailMaker Product Overview
  • InVivo Therapeutics Corp – Key Competitors
  • InVivo Therapeutics Corp – Key Employees
  • InVivo Therapeutics Corp – Locations And Subsidiaries
  • Head Office
  • Recent Developments
  • InVivo Therapeutics Corp, Recent Developments
  • Oct 22, 2019: InVivo Therapeutics provides enrollment update for INSPIRE 2.0 Study for the treatment of Acute Spinal Cord Injury
  • Jul 16, 2019: InVivo Therapeutics announces publication of CONTEMPO registry study data in Peer-Reviewed Journal Spinal Cord
  • May 29, 2019: InVivo Therapeutics announces enrollment of first two patients into The INSPIRE 2.0 Study for the treatment of acute spinal cord injury
  • Apr 17, 2019: InVivo Therapeutics announces presentation of twelve-month results from the INSPIRE study of the investigational Neuro-Spinal Scaffold in Acute Thoracic Complete Spinal Cord Injury
  • Oct 01, 2018: InVivo Therapeutics announces publication of Neuro-Spinal Scaffold preclinical data in peer-reviewed journal Biomaterials
  • Aug 28, 2018: InVivo Therapeutics announces complete 12-month data from the INSPIRE study of the investigational neuro-spinal scaffold in acute thoracic complete spinal cord injury
  • May 02, 2018: InVivo Therapeutics Announces Presentation of Complete Six-Month Primary Endpoint Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold in Acute Thoracic Complete Spinal Cord Injury
  • Mar 19, 2018: InVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study (the CONTEMPO Registry Study) Findings
  • Mar 08, 2018: InVivo Therapeutics Receives FDA Approval for Pivotal, Randomized, Controlled Trial of the Neuro-Spinal Scaffold in Patients with Acute Spinal Cord Injury
  • Feb 05, 2018: InVivo Therapeutics Announces Appointment of Richard Toselli, M.D., as President and Chief Executive Officer
  • Appendix
  • Methodology
  • About the Author
  • Contact Us
  • Disclaimer

Companies Mentioned

  • American Scitech Inc
  • Microbot Medical Inc
  • Acorda Therapeutics Inc

For more information about this company profile visit https://www.researchandmarkets.com/r/y8pbg5



Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900